Largest Phase 3 Trial of Psilocybin for Depression Has Begun | Psychedelic spotlight

psilocybin for depression

As our social fabric is unraveling and rates of depression continue to rise, affecting an estimated 310 million people worldwide, psilocybin research has given us a glimmer of hope that things may be changing for the better. The largest Phase 3 clinical trial investigating the safety, efficacy, and tolerability of psilocybin as a treatment for … Read more

Single Dose Of Psilocybin Causes Long-Term Remission Of Depression In Over 50% Of Cancer Patients | Psychedelic spotlight

Single Dose Of Psilocybin Causes Long-Term Remission Of Depression In Over 50% Of Cancer Patients |  Psychedelic spotlight

Great news for those researching new treatments for depression in cancer patients! Positive long-term follow-up data has just been released from Sunstone Therapies investigator-initiated Phase 2 study evaluating synthetic psilocybin COMPASS Pathways. Administration of a single 25 mg dose of psilocybin combined with psychological support resulted in 57% of patients sustaining remission of depression, with … Read more